The Long and Winding Road to Cardiac Regeneration
![](/bundles/mdpisciprofileslink/img/unknown-user.png)
Round 1
Reviewer 1 Report
This is a very comprehensive review of cardiac regeneration with updated information. However, the manuscript may be improved if the following questions can be addressed.
1. Concept of cardiac regeneration. What needs to be done beyond repair and enhancement of structures and function of damaged myocardium. Can we or do we have the chance to rebuild the heart with current knowledge?
2. Do adult cardiac stem cells exist?
3. Authors described several approaches for cardiac regeneration. Which technology or combination of technologies has the most potential based on current data?
4. In the future directions, authors discussed cardioid and chip-on-chip models of cardiac regeneration in vitro. Please discuss the potential limitations of these technologies when applying for in vivo treatments.
Author Response
Please see the attachment
Author Response File: Author Response.docx
Reviewer 2 Report
This paper reviews current advancements and strategies for cardiac regeneration, which aim to repair and enhance the structure and function of damaged myocardium. It discusses stem cell-based therapies, tissue engineering, organoids and chips, and other approaches being studied. Despite significant progress, several challenges remain in the field, such as enhancing cell survival and engraftment, and ensuring the long-term functionality of engineered constructs. With further research and development, effective therapies to restore cardiac function could greatly improve the quality of life for individuals with heart diseases. I read this paper with great interest and this paper is well written and organized. I have few comments and hope can improve the paper.
· 1. The review paper lacks details on the actual implementation of the different strategies discussed. While the paper provides an overview of current advancements and strategies, the practical applications of these approaches are not discussed in detail.
· 2. It is better to provide insight into the potential risks associated with the various strategies discussed. This information is important to fully evaluate the safety and efficacy of cardiac regeneration therapies.
· 3. A more comprehensive exploration of the preclinical and clinical trials of engineered cardiac constructs, as well as their potential for therapeutic applications, could provide valuable insight.
Author Response
Please see the attachment
Author Response File: Author Response.docx